1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

17 May 2024
Admin
News Article

Ocugen Completes Dosing in Phase 1/2 GARDIAN Trial for OCU410ST Gene Therapy

Ocugen Completes Dosing of Stargardt Disease Patients in Phase 1/2 GARDIAN Trial for OCU410ST Gene Therapy

Overview

Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on developing novel gene and cell therapies as well as vaccines, has announced the completion of dosing in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA). This treatment is intended as a one-time therapy for Stargardt disease, aimed at modifying the gene associated with the condition.

Words from CMO: Ocugen

Dr. Huma Qamar, Ocugen’s Chief Medical Officer, highlighted the importance of reaching this milestone in the trial.
She expressed optimism regarding the positive safety and tolerability profile demonstrated by OCU410ST, indicating the potential for higher doses as the study progresses.
The company plans to share initial safety and efficacy data from Phase 1 soon.

Stargardt Disease & OCU410ST

Stargardt disease, which lacks FDA-approved treatments, presents a significant medical challenge.
Dr. Benjamin Bakall, Director of Clinical Research at Associated Retina Consultants, emphasized the potential of OCU410ST to provide hope for patients with this condition.
The completion of dosing for Cohort 2 represents a crucial advancement.

Safety Data Review Meeting

The trial’s Data and Safety Monitoring Board will meet next month to review safety data before advancing to Cohort 3, which involves administering the highest dose.
The GARDian trial evaluates the safety and efficacy of OCU410ST in subjects with Stargardt disease, conducted in two phases.

Stargardt Disease

Stargardt disease affects approximately 100,000 individuals in the United States and Europe, leading to progressive vision loss due to retinal degeneration.
OCU410ST employs an AAV delivery platform to deliver the RORA gene, targeting pathways associated with Stargardt disease.
Ocugen
Ocugen is dedicated to addressing the unmet needs of individuals with inherited retinal diseases.
An update on the OCU410ST clinical trial is anticipated in the third quarter of 2024.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!